ERLOTINIB HEATON 100 mg Romania - rumeno - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

erlotinib heaton 100 mg

synthon hispania sl - spania - erlotinibum - compr. film. - 100mg - alte antineoplazice inhibitori de protein-kinaza

ERLOTINIB HEATON 150 mg Romania - rumeno - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

erlotinib heaton 150 mg

synthon hispania sl - spania - erlotinibum - compr. film. - 150mg - alte antineoplazice inhibitori de protein-kinaza

ERLOTINIB ZENTIVA 100 mg Romania - rumeno - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

erlotinib zentiva 100 mg

synthon hispania sl - spania - erlotinibum - compr. film. - 100mg - inhibitori de protein-kinaza inhibitori ai tirozin kinazei (egfr)

ERLOTINIB ZENTIVA 150 mg Romania - rumeno - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

erlotinib zentiva 150 mg

synthon hispania sl - spania - erlotinibum - compr. film. - 150mg - inhibitori de protein-kinaza inhibitori ai tirozin kinazei (egfr)

ERLOTINIB ZENTIVA 25 mg Romania - rumeno - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

erlotinib zentiva 25 mg

synthon hispania sl - spania - erlotinibum - compr. film. - 25mg - alte antineoplazice inhibitori de protein-kinaza

PEMETREXED TEVA 25 mg/ml Romania - rumeno - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

pemetrexed teva 25 mg/ml

pharmachemie b.v. - olanda - pemetrexedum - conc. pt. sol. perf. - 25mg/ml - antimetaboliti analogi ai acidului folic

Imfinzi Unione Europea - rumeno - EMA (European Medicines Agency)

imfinzi

astrazeneca ab - durvalumab - carcinom, pulmonar non-celulă mică - agenți antineoplazici - non-small cell lung cancer (nsclc)imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (nsclc) in adults whose tumours express pd-l1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5. imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic nsclc with no sensitising egfr mutations or alk positive mutations. small cell lung cancer (sclc)imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (es-sclc). biliary tract cancer (btc)imfinzi in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (btc). hepatocellular carcinoma (hcc)imfinzi in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc).

ERLOTINIB TERAPIA 100 mg Romania - rumeno - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

erlotinib terapia 100 mg

sun pharmaceutical industries (europe) b.v. - olanda - erlotinibum - compr. film. - 100mg - alte antineoplazice inhibitori de protein-kinaza

ERLOTINIB TERAPIA 150 mg Romania - rumeno - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

erlotinib terapia 150 mg

sun pharmaceutical industries (europe) b.v. - olanda - erlotinibum - compr. film. - 150mg - alte antineoplazice inhibitori de protein-kinaza

ERLOTINIB TERAPIA 25 mg Romania - rumeno - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

erlotinib terapia 25 mg

sun pharmaceutical industries (europe) b.v. - olanda - erlotinibum - compr. film. - 25mg - alte antineoplazice inhibitori de protein-kinaza